Table 3

Incidence rates and adjusted rate ratio estimates in new users of long-acting bronchodilators

Adverse eventsTiotropium, n=4767LABA,* n=6073CrudeAdjusted
nPyrsRatenPyrsRateRRHR95% CI
Death (any)15227755.4817023037.380.740.700.56 to 0.89
Cardiovascular
 Aneurysm1727650.611322980.571.090.960.44 to 2.05
 Atrial fibrillation/flutter8727253.197622723.340.950.990.71 to 1.38
 Cardiac arrest327740.11423030.170.65
 Coronary artery disease12527124.6110222554.521.021.110.84 to 1.47
 Angina5327461.933822751.671.161.380.88 to 2.16
 Myocardial infarction3527651.272322971.001.261.260.72 to 2.21
 Heart failure9327383.4010522654.640.730.850.63 to 1.14
 Hypertension16926546.3716322327.300.871.030.81 to 1.29
 Stroke4527501.642822961.221.341.490.91 to 2.45
 Syncope3527621.273522891.530.830.940.57 to 1.55
 Tachycardia1527690.541122960.481.131.080.48 to 2.41
 Ventricular tachycardia227740.07123020.041.66
Respiratory
 Asthma exacerbation9827163.61395214018.460.200.460.36 to 0.57
 COPD exacerbation287263710.88313216814.440.750.950.80 to 1.12
 Pneumonia3527571.273422971.480.860.960.58 to 1.58
Other
 Constipation13727085.0612422515.510.920.950.74 to 1.23
 Dry mouth2627620.94722990.303.093.661.52 to 8.78
 Dysphagia3927571.413222921.401.011.020.62 to 1.69
 Paralytic ileus/bowel obstruction427750.14723010.300.47
 Renal failure3427601.231922950.831.491.400.77 to 2.55
 Urinary retention2927651.052522901.090.960.970.55 to 1.70
 Tremor1627690.582322921.000.580.620.31 to 1.22
  • * Single-ingredient formulations.

  • Rate per 100 person-years.

  • ‘─’ signifies the adjusted results are not presented as there are <5 events in either tiotropium or LABA users.

  • COPD, chronic obstructive pulmonary disease; LABA, long-acting β-agonists; N, number of patients; Pyrs, person-years at risk; RR, rate ratio; HR, relative hazard estimated using Cox' proportional hazards model adjusted for propensity score.